nodes	percent_of_prediction	percent_of_DWPC	metapath
Irbesartan—Distention—Octreotide—thymus cancer	0.0427	0.0555	CcSEcCtD
Irbesartan—Abnormal faeces—Octreotide—thymus cancer	0.0352	0.0458	CcSEcCtD
Irbesartan—Diabetic—Octreotide—thymus cancer	0.0301	0.0392	CcSEcCtD
Irbesartan—Breast feeding—Octreotide—thymus cancer	0.0288	0.0374	CcSEcCtD
Irbesartan—Ear infection—Octreotide—thymus cancer	0.0237	0.0308	CcSEcCtD
Irbesartan—Prostatic disorder—Octreotide—thymus cancer	0.0237	0.0308	CcSEcCtD
Irbesartan—Trauma—Octreotide—thymus cancer	0.0211	0.0275	CcSEcCtD
Irbesartan—Epigastric pain—Octreotide—thymus cancer	0.0208	0.0271	CcSEcCtD
Irbesartan—Creatine phosphokinase increased—Octreotide—thymus cancer	0.0191	0.0249	CcSEcCtD
Irbesartan—Anorectal disorder—Octreotide—thymus cancer	0.0191	0.0249	CcSEcCtD
Irbesartan—JUN—neck—thymus cancer	0.0146	0.0652	CbGeAlD
Irbesartan—Blood creatine phosphokinase increased—Octreotide—thymus cancer	0.0146	0.019	CcSEcCtD
Irbesartan—Numbness—Octreotide—thymus cancer	0.0121	0.0158	CcSEcCtD
Irbesartan—Sensory loss—Octreotide—thymus cancer	0.0116	0.0151	CcSEcCtD
Irbesartan—Jaundice cholestatic—Octreotide—thymus cancer	0.0114	0.0149	CcSEcCtD
Irbesartan—AGTR1—neck—thymus cancer	0.011	0.0491	CbGeAlD
Irbesartan—JUN—hematopoietic system—thymus cancer	0.0109	0.0485	CbGeAlD
Irbesartan—Drug interaction—Octreotide—thymus cancer	0.0108	0.0141	CcSEcCtD
Irbesartan—JUN—epithelium—thymus cancer	0.00996	0.0444	CbGeAlD
Irbesartan—Hyperkalaemia—Octreotide—thymus cancer	0.00988	0.0129	CcSEcCtD
Irbesartan—Wheezing—Octreotide—thymus cancer	0.00977	0.0127	CcSEcCtD
Irbesartan—EDNRA—cardiac atrium—thymus cancer	0.00907	0.0404	CbGeAlD
Irbesartan—EDNRA—pituitary gland—thymus cancer	0.00886	0.0394	CbGeAlD
Irbesartan—Sleep disorder—Octreotide—thymus cancer	0.00843	0.011	CcSEcCtD
Irbesartan—Diabetes mellitus—Octreotide—thymus cancer	0.00839	0.0109	CcSEcCtD
Irbesartan—JUN—cardiac atrium—thymus cancer	0.00827	0.0368	CbGeAlD
Irbesartan—Gastroenteritis—Octreotide—thymus cancer	0.00824	0.0107	CcSEcCtD
Irbesartan—AGTR1—hematopoietic system—thymus cancer	0.0082	0.0365	CbGeAlD
Irbesartan—JUN—pituitary gland—thymus cancer	0.00808	0.036	CbGeAlD
Irbesartan—Injury—Octreotide—thymus cancer	0.00794	0.0103	CcSEcCtD
Irbesartan—Hot flush—Octreotide—thymus cancer	0.00781	0.0102	CcSEcCtD
Irbesartan—Menopausal symptoms—Octreotide—thymus cancer	0.00774	0.0101	CcSEcCtD
Irbesartan—Visual disturbance—Octreotide—thymus cancer	0.0077	0.01	CcSEcCtD
Irbesartan—JUN—lymphoid tissue—thymus cancer	0.00767	0.0342	CbGeAlD
Irbesartan—EDNRA—thyroid gland—thymus cancer	0.00764	0.034	CbGeAlD
Irbesartan—Arthritis—Octreotide—thymus cancer	0.00751	0.00977	CcSEcCtD
Irbesartan—AGTR1—epithelium—thymus cancer	0.0075	0.0334	CbGeAlD
Irbesartan—JUN—bone marrow—thymus cancer	0.00698	0.0311	CbGeAlD
Irbesartan—JUN—thyroid gland—thymus cancer	0.00697	0.031	CbGeAlD
Irbesartan—EDNRA—lung—thymus cancer	0.00694	0.0309	CbGeAlD
Irbesartan—Abdominal pain upper—Octreotide—thymus cancer	0.00667	0.00867	CcSEcCtD
Irbesartan—Cramp muscle—Octreotide—thymus cancer	0.00657	0.00855	CcSEcCtD
Irbesartan—Nasopharyngitis—Octreotide—thymus cancer	0.00653	0.00849	CcSEcCtD
Irbesartan—Muscular weakness—Octreotide—thymus cancer	0.00644	0.00838	CcSEcCtD
Irbesartan—Abdominal distension—Octreotide—thymus cancer	0.00635	0.00826	CcSEcCtD
Irbesartan—JUN—lung—thymus cancer	0.00633	0.0282	CbGeAlD
Irbesartan—Asthma—Octreotide—thymus cancer	0.00631	0.00821	CcSEcCtD
Irbesartan—Influenza—Octreotide—thymus cancer	0.00631	0.00821	CcSEcCtD
Irbesartan—AGTR1—cardiac atrium—thymus cancer	0.00623	0.0277	CbGeAlD
Irbesartan—Pancreatitis—Octreotide—thymus cancer	0.00619	0.00805	CcSEcCtD
Irbesartan—AGTR1—pituitary gland—thymus cancer	0.00609	0.0271	CbGeAlD
Irbesartan—Upper respiratory tract infection—Octreotide—thymus cancer	0.00587	0.00763	CcSEcCtD
Irbesartan—AGTR1—lymphoid tissue—thymus cancer	0.00578	0.0257	CbGeAlD
Irbesartan—Weight increased—Octreotide—thymus cancer	0.00574	0.00747	CcSEcCtD
Irbesartan—Hyperglycaemia—Octreotide—thymus cancer	0.00569	0.00741	CcSEcCtD
Irbesartan—Pneumonia—Octreotide—thymus cancer	0.00566	0.00736	CcSEcCtD
Irbesartan—Jaundice—Octreotide—thymus cancer	0.00548	0.00713	CcSEcCtD
Irbesartan—Urinary tract infection—Octreotide—thymus cancer	0.00547	0.00711	CcSEcCtD
Irbesartan—Conjunctivitis—Octreotide—thymus cancer	0.00547	0.00711	CcSEcCtD
Irbesartan—Hepatobiliary disease—Octreotide—thymus cancer	0.00532	0.00692	CcSEcCtD
Irbesartan—Epistaxis—Octreotide—thymus cancer	0.00531	0.0069	CcSEcCtD
Irbesartan—AGTR1—thyroid gland—thymus cancer	0.00525	0.0234	CbGeAlD
Irbesartan—Bradycardia—Octreotide—thymus cancer	0.00514	0.00669	CcSEcCtD
Irbesartan—Rhinitis—Octreotide—thymus cancer	0.00506	0.00659	CcSEcCtD
Irbesartan—Hepatitis—Octreotide—thymus cancer	0.00505	0.00657	CcSEcCtD
Irbesartan—Hypoaesthesia—Octreotide—thymus cancer	0.00503	0.00654	CcSEcCtD
Irbesartan—Pharyngitis—Octreotide—thymus cancer	0.00501	0.00652	CcSEcCtD
Irbesartan—Oedema peripheral—Octreotide—thymus cancer	0.00498	0.00647	CcSEcCtD
Irbesartan—Visual impairment—Octreotide—thymus cancer	0.00487	0.00633	CcSEcCtD
Irbesartan—AGTR1—lung—thymus cancer	0.00477	0.0212	CbGeAlD
Irbesartan—EDNRA—lymph node—thymus cancer	0.00474	0.0211	CbGeAlD
Irbesartan—Tinnitus—Octreotide—thymus cancer	0.00471	0.00613	CcSEcCtD
Irbesartan—Cardiac disorder—Octreotide—thymus cancer	0.00469	0.0061	CcSEcCtD
Irbesartan—Flushing—Octreotide—thymus cancer	0.00469	0.0061	CcSEcCtD
Irbesartan—Immune system disorder—Octreotide—thymus cancer	0.00456	0.00594	CcSEcCtD
Irbesartan—Arrhythmia—Octreotide—thymus cancer	0.00451	0.00587	CcSEcCtD
Irbesartan—CYP2C8—hematopoietic system—thymus cancer	0.00445	0.0198	CbGeAlD
Irbesartan—Malnutrition—Octreotide—thymus cancer	0.0044	0.00572	CcSEcCtD
Irbesartan—Erythema—Octreotide—thymus cancer	0.0044	0.00572	CcSEcCtD
Irbesartan—Flatulence—Octreotide—thymus cancer	0.00433	0.00564	CcSEcCtD
Irbesartan—JUN—lymph node—thymus cancer	0.00433	0.0193	CbGeAlD
Irbesartan—Tension—Octreotide—thymus cancer	0.00431	0.00561	CcSEcCtD
Irbesartan—Nervousness—Octreotide—thymus cancer	0.00427	0.00556	CcSEcCtD
Irbesartan—Muscle spasms—Octreotide—thymus cancer	0.00423	0.0055	CcSEcCtD
Irbesartan—CYP1A2—hematopoietic system—thymus cancer	0.00416	0.0185	CbGeAlD
Irbesartan—Vision blurred—Octreotide—thymus cancer	0.00414	0.00539	CcSEcCtD
Irbesartan—Tremor—Octreotide—thymus cancer	0.00412	0.00536	CcSEcCtD
Irbesartan—Ill-defined disorder—Octreotide—thymus cancer	0.00408	0.00531	CcSEcCtD
Irbesartan—Anaemia—Octreotide—thymus cancer	0.00406	0.00529	CcSEcCtD
Irbesartan—Agitation—Octreotide—thymus cancer	0.00404	0.00526	CcSEcCtD
Irbesartan—Malaise—Octreotide—thymus cancer	0.00397	0.00516	CcSEcCtD
Irbesartan—CYP2C9—hematopoietic system—thymus cancer	0.00395	0.0176	CbGeAlD
Irbesartan—Vertigo—Octreotide—thymus cancer	0.00395	0.00514	CcSEcCtD
Irbesartan—Syncope—Octreotide—thymus cancer	0.00394	0.00513	CcSEcCtD
Irbesartan—Loss of consciousness—Octreotide—thymus cancer	0.00386	0.00503	CcSEcCtD
Irbesartan—Cough—Octreotide—thymus cancer	0.00384	0.00499	CcSEcCtD
Irbesartan—Hypertension—Octreotide—thymus cancer	0.0038	0.00494	CcSEcCtD
Irbesartan—Myalgia—Octreotide—thymus cancer	0.00374	0.00487	CcSEcCtD
Irbesartan—Arthralgia—Octreotide—thymus cancer	0.00374	0.00487	CcSEcCtD
Irbesartan—Chest pain—Octreotide—thymus cancer	0.00374	0.00487	CcSEcCtD
Irbesartan—Anxiety—Octreotide—thymus cancer	0.00373	0.00485	CcSEcCtD
Irbesartan—Unspecified disorder of skin and subcutaneous tissue—Octreotide—thymus cancer	0.00372	0.00484	CcSEcCtD
Irbesartan—Discomfort—Octreotide—thymus cancer	0.0037	0.00481	CcSEcCtD
Irbesartan—Dry mouth—Octreotide—thymus cancer	0.00366	0.00476	CcSEcCtD
Irbesartan—PTGS1—hematopoietic system—thymus cancer	0.00361	0.0161	CbGeAlD
Irbesartan—Anaphylactic shock—Octreotide—thymus cancer	0.00359	0.00467	CcSEcCtD
Irbesartan—Oedema—Octreotide—thymus cancer	0.00359	0.00467	CcSEcCtD
Irbesartan—Infection—Octreotide—thymus cancer	0.00357	0.00464	CcSEcCtD
Irbesartan—Shock—Octreotide—thymus cancer	0.00353	0.00459	CcSEcCtD
Irbesartan—Nervous system disorder—Octreotide—thymus cancer	0.00352	0.00458	CcSEcCtD
Irbesartan—Thrombocytopenia—Octreotide—thymus cancer	0.00351	0.00457	CcSEcCtD
Irbesartan—Tachycardia—Octreotide—thymus cancer	0.0035	0.00456	CcSEcCtD
Irbesartan—Skin disorder—Octreotide—thymus cancer	0.00349	0.00453	CcSEcCtD
Irbesartan—Hyperhidrosis—Octreotide—thymus cancer	0.00347	0.00451	CcSEcCtD
Irbesartan—Anorexia—Octreotide—thymus cancer	0.00342	0.00445	CcSEcCtD
Irbesartan—CYP2C8—pituitary gland—thymus cancer	0.0033	0.0147	CbGeAlD
Irbesartan—PTGS1—epithelium—thymus cancer	0.0033	0.0147	CbGeAlD
Irbesartan—Musculoskeletal discomfort—Octreotide—thymus cancer	0.00327	0.00425	CcSEcCtD
Irbesartan—AGTR1—lymph node—thymus cancer	0.00326	0.0145	CbGeAlD
Irbesartan—Paraesthesia—Octreotide—thymus cancer	0.00322	0.00419	CcSEcCtD
Irbesartan—Dyspnoea—Octreotide—thymus cancer	0.0032	0.00416	CcSEcCtD
Irbesartan—Somnolence—Octreotide—thymus cancer	0.00319	0.00415	CcSEcCtD
Irbesartan—Dyspepsia—Octreotide—thymus cancer	0.00316	0.00411	CcSEcCtD
Irbesartan—Decreased appetite—Octreotide—thymus cancer	0.00312	0.00406	CcSEcCtD
Irbesartan—Gastrointestinal disorder—Octreotide—thymus cancer	0.0031	0.00403	CcSEcCtD
Irbesartan—Fatigue—Octreotide—thymus cancer	0.00309	0.00402	CcSEcCtD
Irbesartan—Pain—Octreotide—thymus cancer	0.00307	0.00399	CcSEcCtD
Irbesartan—Constipation—Octreotide—thymus cancer	0.00307	0.00399	CcSEcCtD
Irbesartan—CYP3A4—hematopoietic system—thymus cancer	0.00301	0.0134	CbGeAlD
Irbesartan—CYP2D6—hematopoietic system—thymus cancer	0.00296	0.0132	CbGeAlD
Irbesartan—Feeling abnormal—Octreotide—thymus cancer	0.00296	0.00385	CcSEcCtD
Irbesartan—Gastrointestinal pain—Octreotide—thymus cancer	0.00293	0.00382	CcSEcCtD
Irbesartan—Urticaria—Octreotide—thymus cancer	0.00285	0.00371	CcSEcCtD
Irbesartan—Abdominal pain—Octreotide—thymus cancer	0.00284	0.00369	CcSEcCtD
Irbesartan—Body temperature increased—Octreotide—thymus cancer	0.00284	0.00369	CcSEcCtD
Irbesartan—PTGS1—cardiac atrium—thymus cancer	0.00274	0.0122	CbGeAlD
Irbesartan—PTGS1—pituitary gland—thymus cancer	0.00268	0.0119	CbGeAlD
Irbesartan—CYP1A2—thyroid gland—thymus cancer	0.00266	0.0119	CbGeAlD
Irbesartan—Hypersensitivity—Octreotide—thymus cancer	0.00264	0.00344	CcSEcCtD
Irbesartan—Asthenia—Octreotide—thymus cancer	0.00257	0.00335	CcSEcCtD
Irbesartan—Pruritus—Octreotide—thymus cancer	0.00254	0.0033	CcSEcCtD
Irbesartan—Diarrhoea—Octreotide—thymus cancer	0.00246	0.00319	CcSEcCtD
Irbesartan—CYP1A2—lung—thymus cancer	0.00242	0.0108	CbGeAlD
Irbesartan—Dizziness—Octreotide—thymus cancer	0.00237	0.00309	CcSEcCtD
Irbesartan—PTGS1—thyroid gland—thymus cancer	0.00231	0.0103	CbGeAlD
Irbesartan—Vomiting—Octreotide—thymus cancer	0.00228	0.00297	CcSEcCtD
Irbesartan—Rash—Octreotide—thymus cancer	0.00226	0.00294	CcSEcCtD
Irbesartan—Dermatitis—Octreotide—thymus cancer	0.00226	0.00294	CcSEcCtD
Irbesartan—Headache—Octreotide—thymus cancer	0.00225	0.00292	CcSEcCtD
Irbesartan—Nausea—Octreotide—thymus cancer	0.00213	0.00277	CcSEcCtD
Irbesartan—PTGS1—lung—thymus cancer	0.00209	0.00933	CbGeAlD
Irbesartan—PTGS1—lymph node—thymus cancer	0.00143	0.00638	CbGeAlD
Irbesartan—JUN—Pre-NOTCH Transcription and Translation—MAML2—thymus cancer	0.000435	0.0647	CbGpPWpGaD
Irbesartan—JUN—Pre-NOTCH Expression and Processing—MAML2—thymus cancer	0.000306	0.0455	CbGpPWpGaD
Irbesartan—JUN—Regulation of toll-like receptor signaling pathway—CYLD—thymus cancer	0.000156	0.0232	CbGpPWpGaD
Irbesartan—JUN—Signaling by NOTCH—MAML2—thymus cancer	0.000151	0.0224	CbGpPWpGaD
Irbesartan—JUN—IL12 signaling mediated by STAT4—CD4—thymus cancer	0.00015	0.0222	CbGpPWpGaD
Irbesartan—JUN—Calcium signaling in the CD4+ TCR pathway—IL2—thymus cancer	0.000141	0.021	CbGpPWpGaD
Irbesartan—JUN—Downstream signaling in naïve CD8+ T cells—CD8A—thymus cancer	0.000139	0.0206	CbGpPWpGaD
Irbesartan—JUN—IL12 signaling mediated by STAT4—IL2—thymus cancer	0.000138	0.0204	CbGpPWpGaD
Irbesartan—JUN—Validated transcriptional targets of AP1 family members Fra1 and Fra2—CDKN2A—thymus cancer	0.000134	0.0199	CbGpPWpGaD
Irbesartan—UGT1A3—Aryl Hydrocarbon Receptor Pathway—IL2—thymus cancer	0.000121	0.018	CbGpPWpGaD
Irbesartan—JUN—IL-5 Signaling Pathway—IL2—thymus cancer	0.000109	0.0162	CbGpPWpGaD
Irbesartan—JUN—TCR Signaling Pathway—CD8A—thymus cancer	0.000108	0.0161	CbGpPWpGaD
Irbesartan—JUN—IL-2 Signaling Pathway—IL2—thymus cancer	0.000105	0.0156	CbGpPWpGaD
Irbesartan—JUN—Aryl Hydrocarbon Receptor Pathway—IL2—thymus cancer	9.78e-05	0.0145	CbGpPWpGaD
Irbesartan—JUN—Estrogen signaling pathway—AKT1—thymus cancer	9.23e-05	0.0137	CbGpPWpGaD
Irbesartan—JUN—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2—thymus cancer	9.15e-05	0.0136	CbGpPWpGaD
Irbesartan—JUN—Pre-NOTCH Transcription and Translation—TP53—thymus cancer	9.08e-05	0.0135	CbGpPWpGaD
Irbesartan—JUN—IL2-mediated signaling events—IL2—thymus cancer	8.6e-05	0.0128	CbGpPWpGaD
Irbesartan—AGTR1—Allograft Rejection—IL2—thymus cancer	8.49e-05	0.0126	CbGpPWpGaD
Irbesartan—JUN—Regulation of retinoblastoma protein—CDKN2A—thymus cancer	8.45e-05	0.0126	CbGpPWpGaD
Irbesartan—JUN—AP-1 transcription factor network—CDKN2A—thymus cancer	8.07e-05	0.012	CbGpPWpGaD
Irbesartan—JUN—Nephrin/Neph1 signaling in the kidney podocyte—AKT1—thymus cancer	7.89e-05	0.0117	CbGpPWpGaD
Irbesartan—JUN—Signaling mediated by p38-alpha and p38-beta—TP53—thymus cancer	7.82e-05	0.0116	CbGpPWpGaD
Irbesartan—JUN—Downstream signaling in naïve CD8+ T cells—IL2—thymus cancer	7.33e-05	0.0109	CbGpPWpGaD
Irbesartan—JUN—Regulation of nuclear beta catenin signaling and target gene transcription—CDKN2A—thymus cancer	7.25e-05	0.0108	CbGpPWpGaD
Irbesartan—JUN—Regulation of Telomerase—IL2—thymus cancer	7.15e-05	0.0106	CbGpPWpGaD
Irbesartan—EDNRA—Endothelins—AKT1—thymus cancer	7.03e-05	0.0104	CbGpPWpGaD
Irbesartan—JUN—ATM Signaling Pathway—TP53—thymus cancer	7.02e-05	0.0104	CbGpPWpGaD
Irbesartan—JUN—AP-1 transcription factor network—IL2—thymus cancer	6.99e-05	0.0104	CbGpPWpGaD
Irbesartan—JUN—Apoptosis—CDKN2A—thymus cancer	6.97e-05	0.0104	CbGpPWpGaD
Irbesartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—AKT1—thymus cancer	6.64e-05	0.00986	CbGpPWpGaD
Irbesartan—JUN—Apoptosis Modulation and Signaling—CDKN2A—thymus cancer	6.54e-05	0.00971	CbGpPWpGaD
Irbesartan—JUN—CD40/CD40L signaling—AKT1—thymus cancer	6.45e-05	0.00958	CbGpPWpGaD
Irbesartan—JUN—Pre-NOTCH Expression and Processing—TP53—thymus cancer	6.39e-05	0.00949	CbGpPWpGaD
Irbesartan—JUN—TCR Signaling Pathway—CD4—thymus cancer	6.21e-05	0.00923	CbGpPWpGaD
Irbesartan—JUN—Glucocorticoid receptor regulatory network—IL2—thymus cancer	6.16e-05	0.00915	CbGpPWpGaD
Irbesartan—JUN—IL-5 Signaling Pathway—AKT1—thymus cancer	5.93e-05	0.00881	CbGpPWpGaD
Irbesartan—JUN—Senescence-Associated Secretory Phenotype (SASP)—CDKN2A—thymus cancer	5.83e-05	0.00866	CbGpPWpGaD
Irbesartan—JUN—Senescence and Autophagy in Cancer—CDKN2A—thymus cancer	5.83e-05	0.00866	CbGpPWpGaD
Irbesartan—JUN—ErbB2/ErbB3 signaling events—AKT1—thymus cancer	5.81e-05	0.00864	CbGpPWpGaD
Irbesartan—JUN—IL-2 Signaling Pathway—AKT1—thymus cancer	5.7e-05	0.00847	CbGpPWpGaD
Irbesartan—JUN—TWEAK Signaling Pathway—AKT1—thymus cancer	5.7e-05	0.00847	CbGpPWpGaD
Irbesartan—JUN—Copper homeostasis—TP53—thymus cancer	5.69e-05	0.00846	CbGpPWpGaD
Irbesartan—JUN—DNA Damage Response (only ATM dependent)—CDKN2A—thymus cancer	5.66e-05	0.0084	CbGpPWpGaD
Irbesartan—JUN—ErbB Signaling Pathway—TP53—thymus cancer	5.52e-05	0.0082	CbGpPWpGaD
Irbesartan—JUN—Integrin-linked kinase signaling—AKT1—thymus cancer	5.4e-05	0.00802	CbGpPWpGaD
Irbesartan—JUN—Oxidative Stress Induced Senescence—CDKN2A—thymus cancer	5.28e-05	0.00783	CbGpPWpGaD
Irbesartan—JUN—IL6-mediated signaling events—AKT1—thymus cancer	5.21e-05	0.00774	CbGpPWpGaD
Irbesartan—JUN—IL-3 Signaling Pathway—AKT1—thymus cancer	5.04e-05	0.00749	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—CYLD—thymus cancer	5.01e-05	0.00744	CbGpPWpGaD
Irbesartan—JUN—Copper homeostasis—AKT1—thymus cancer	4.81e-05	0.00714	CbGpPWpGaD
Irbesartan—JUN—Fc epsilon receptor (FCERI) signaling—KIT—thymus cancer	4.73e-05	0.00702	CbGpPWpGaD
Irbesartan—JUN—FGF signaling pathway—AKT1—thymus cancer	4.66e-05	0.00693	CbGpPWpGaD
Irbesartan—JUN—IL-1 signaling pathway—AKT1—thymus cancer	4.6e-05	0.00683	CbGpPWpGaD
Irbesartan—JUN—RANKL/RANK Signaling Pathway—AKT1—thymus cancer	4.6e-05	0.00683	CbGpPWpGaD
Irbesartan—JUN—AP-1 transcription factor network—TP53—thymus cancer	4.49e-05	0.00667	CbGpPWpGaD
Irbesartan—JUN—Fc-epsilon receptor I signaling in mast cells—AKT1—thymus cancer	4.23e-05	0.00628	CbGpPWpGaD
Irbesartan—JUN—Endothelins—AKT1—thymus cancer	4.12e-05	0.00612	CbGpPWpGaD
Irbesartan—JUN—LPA receptor mediated events—AKT1—thymus cancer	4.07e-05	0.00605	CbGpPWpGaD
Irbesartan—JUN—TSH signaling pathway—AKT1—thymus cancer	3.97e-05	0.0059	CbGpPWpGaD
Irbesartan—JUN—AGE/RAGE pathway—AKT1—thymus cancer	3.97e-05	0.0059	CbGpPWpGaD
Irbesartan—JUN—HIF-1-alpha transcription factor network—AKT1—thymus cancer	3.97e-05	0.0059	CbGpPWpGaD
Irbesartan—JUN—Glucocorticoid receptor regulatory network—TP53—thymus cancer	3.95e-05	0.00587	CbGpPWpGaD
Irbesartan—JUN—BCR signaling pathway—AKT1—thymus cancer	3.93e-05	0.00583	CbGpPWpGaD
Irbesartan—JUN—Apoptosis—TP53—thymus cancer	3.88e-05	0.00576	CbGpPWpGaD
Irbesartan—JUN—Regulation of Telomerase—AKT1—thymus cancer	3.88e-05	0.00576	CbGpPWpGaD
Irbesartan—JUN—Cellular Senescence—CDKN2A—thymus cancer	3.69e-05	0.00548	CbGpPWpGaD
Irbesartan—JUN—Apoptosis Modulation and Signaling—TP53—thymus cancer	3.64e-05	0.0054	CbGpPWpGaD
Irbesartan—JUN—Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)—AKT1—thymus cancer	3.41e-05	0.00506	CbGpPWpGaD
Irbesartan—JUN—Regulation of nuclear SMAD2/3 signaling—AKT1—thymus cancer	3.37e-05	0.00501	CbGpPWpGaD
Irbesartan—JUN—Glucocorticoid receptor regulatory network—AKT1—thymus cancer	3.34e-05	0.00496	CbGpPWpGaD
Irbesartan—JUN—Wnt Signaling Pathway and Pluripotency—TP53—thymus cancer	3.32e-05	0.00493	CbGpPWpGaD
Irbesartan—JUN—Apoptosis—AKT1—thymus cancer	3.28e-05	0.00487	CbGpPWpGaD
Irbesartan—JUN—Senescence and Autophagy in Cancer—TP53—thymus cancer	3.25e-05	0.00482	CbGpPWpGaD
Irbesartan—JUN—Signaling by NOTCH—TP53—thymus cancer	3.15e-05	0.00468	CbGpPWpGaD
Irbesartan—JUN—DNA Damage Response (only ATM dependent)—TP53—thymus cancer	3.15e-05	0.00468	CbGpPWpGaD
Irbesartan—JUN—Androgen receptor signaling pathway—AKT1—thymus cancer	3.13e-05	0.00465	CbGpPWpGaD
Irbesartan—JUN—TCR Signaling Pathway—AKT1—thymus cancer	3.1e-05	0.0046	CbGpPWpGaD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—thymus cancer	3.07e-05	0.00455	CbGpPWpGaD
Irbesartan—JUN—TNF alpha Signaling Pathway—AKT1—thymus cancer	3.05e-05	0.00452	CbGpPWpGaD
Irbesartan—JUN—Oxidative Stress Induced Senescence—TP53—thymus cancer	2.94e-05	0.00436	CbGpPWpGaD
Irbesartan—JUN—B Cell Receptor Signaling Pathway—AKT1—thymus cancer	2.92e-05	0.00434	CbGpPWpGaD
Irbesartan—JUN—Immune System—CYLD—thymus cancer	2.92e-05	0.00433	CbGpPWpGaD
Irbesartan—JUN—Toll-like Receptor Signaling Pathway—AKT1—thymus cancer	2.8e-05	0.00417	CbGpPWpGaD
Irbesartan—JUN—Cellular responses to stress—CDKN2A—thymus cancer	2.79e-05	0.00414	CbGpPWpGaD
Irbesartan—JUN—ErbB1 downstream signaling—AKT1—thymus cancer	2.74e-05	0.00407	CbGpPWpGaD
Irbesartan—JUN—TGF-beta Signaling Pathway—TP53—thymus cancer	2.7e-05	0.00401	CbGpPWpGaD
Irbesartan—JUN—DNA Damage Response (only ATM dependent)—AKT1—thymus cancer	2.66e-05	0.00395	CbGpPWpGaD
Irbesartan—JUN—Direct p53 effectors—TP53—thymus cancer	2.58e-05	0.00383	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—MAML2—thymus cancer	2.56e-05	0.0038	CbGpPWpGaD
Irbesartan—JUN—Integrated Breast Cancer Pathway—TP53—thymus cancer	2.43e-05	0.0036	CbGpPWpGaD
Irbesartan—JUN—TGF-beta Signaling Pathway—AKT1—thymus cancer	2.28e-05	0.00339	CbGpPWpGaD
Irbesartan—JUN—MAPK Signaling Pathway—TP53—thymus cancer	2.23e-05	0.00331	CbGpPWpGaD
Irbesartan—JUN—Regulation of toll-like receptor signaling pathway—AKT1—thymus cancer	2.19e-05	0.00325	CbGpPWpGaD
Irbesartan—JUN—BDNF signaling pathway—AKT1—thymus cancer	2.13e-05	0.00316	CbGpPWpGaD
Irbesartan—JUN—Cellular Senescence—TP53—thymus cancer	2.05e-05	0.00305	CbGpPWpGaD
Irbesartan—JUN—Integrated Breast Cancer Pathway—AKT1—thymus cancer	2.05e-05	0.00304	CbGpPWpGaD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—TP53—thymus cancer	2.01e-05	0.00299	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—MAML2—thymus cancer	2.01e-05	0.00298	CbGpPWpGaD
Irbesartan—JUN—Insulin Signaling—AKT1—thymus cancer	1.96e-05	0.00291	CbGpPWpGaD
Irbesartan—JUN—EGF/EGFR Signaling Pathway—AKT1—thymus cancer	1.94e-05	0.00288	CbGpPWpGaD
Irbesartan—JUN—Circadian rythm related genes—TP53—thymus cancer	1.93e-05	0.00287	CbGpPWpGaD
Irbesartan—JUN—MAPK Signaling Pathway—AKT1—thymus cancer	1.88e-05	0.00279	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—KIT—thymus cancer	1.84e-05	0.00273	CbGpPWpGaD
Irbesartan—JUN—Fc epsilon receptor (FCERI) signaling—AKT1—thymus cancer	1.8e-05	0.00268	CbGpPWpGaD
Irbesartan—JUN—Focal Adhesion—AKT1—thymus cancer	1.71e-05	0.00253	CbGpPWpGaD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—AKT1—thymus cancer	1.7e-05	0.00252	CbGpPWpGaD
Irbesartan—JUN—Cellular responses to stress—TP53—thymus cancer	1.55e-05	0.0023	CbGpPWpGaD
Irbesartan—EDNRA—GPCR downstream signaling—IL2—thymus cancer	1.55e-05	0.0023	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—MAML2—thymus cancer	1.5e-05	0.00223	CbGpPWpGaD
Irbesartan—JUN—Immune System—CD8A—thymus cancer	1.43e-05	0.00212	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—IL2—thymus cancer	1.41e-05	0.00209	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—CD4—thymus cancer	1.41e-05	0.00209	CbGpPWpGaD
Irbesartan—AGTR1—GPCR downstream signaling—IL2—thymus cancer	1.21e-05	0.0018	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—KIT—thymus cancer	1.18e-05	0.00175	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—IL2—thymus cancer	1.1e-05	0.00164	CbGpPWpGaD
Irbesartan—JUN—Immune System—KIT—thymus cancer	1.07e-05	0.00159	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—KIT—thymus cancer	9.26e-06	0.00138	CbGpPWpGaD
Irbesartan—EDNRA—GPCR downstream signaling—AKT1—thymus cancer	8.4e-06	0.00125	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—IL2—thymus cancer	8.31e-06	0.00123	CbGpPWpGaD
Irbesartan—JUN—Immune System—CD4—thymus cancer	8.19e-06	0.00122	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—AKT1—thymus cancer	7.62e-06	0.00113	CbGpPWpGaD
Irbesartan—JUN—Immune System—IL2—thymus cancer	7.53e-06	0.00112	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—AKT1—thymus cancer	7.01e-06	0.00104	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—KIT—thymus cancer	6.92e-06	0.00103	CbGpPWpGaD
Irbesartan—AGTR1—GPCR downstream signaling—AKT1—thymus cancer	6.59e-06	0.000978	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—IL2—thymus cancer	6.52e-06	0.000968	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—AKT1—thymus cancer	5.98e-06	0.000888	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—TP53—thymus cancer	5.33e-06	0.000792	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—IL2—thymus cancer	4.87e-06	0.000723	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—AKT1—thymus cancer	4.5e-06	0.000669	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—TP53—thymus cancer	4.19e-06	0.000622	CbGpPWpGaD
Irbesartan—JUN—Immune System—AKT1—thymus cancer	4.08e-06	0.000606	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—AKT1—thymus cancer	3.91e-06	0.000581	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—AKT1—thymus cancer	3.53e-06	0.000525	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—TP53—thymus cancer	3.13e-06	0.000464	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—AKT1—thymus cancer	2.64e-06	0.000392	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—AKT1—thymus cancer	2.2e-06	0.000327	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—AKT1—thymus cancer	1.42e-06	0.000211	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—AKT1—thymus cancer	1.17e-06	0.000174	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—AKT1—thymus cancer	1.16e-06	0.000172	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—AKT1—thymus cancer	9.9e-07	0.000147	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—AKT1—thymus cancer	7.64e-07	0.000113	CbGpPWpGaD
